Tender

PHARMAC TE PĂTAKA WHAIORANGA

28 October 2022

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender (ITT) dated 1 November 2021.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- For new listings, by 4pm on the 12th of November 2022 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <u>https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process</u>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New

Zealand (<u>http://www.pgnz.org.nz/about-us-1/Pharmacode</u>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<u>http://www.nzulm.org.nz/sponsors</u>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

1. Tenders awarded to Pharmaceuticals where no brand is listed

Chemical name	Presentation; Pack size and type	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	
Ramipril ¹	Cap 1.25 mg; 30 capsule blister pack	\$2.30	Tryzan (Viatris)	1 December 2022	1 May 2023	
Ramipril ¹	Cap 2.5 mg; 30 capsule blister pack	\$2.20	Tryzan (Viatris)	1 December 2022	1 May 2023	
Ramipril ¹	Cap 5 mg; 30 capsule blister pack	\$2.25	Tryzan (Viatris)	1 December 2022	1 May 2023	
Ramipril ¹	Cap 10 mg; 30 capsule blister pack	\$2.35	Tryzan (Viatris)	1 December 2022	1 May 2023	
¹ Ramipril capsules will be funded without restrictions from 1 December 2022. Details on this decision is <u>here</u>						



Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

2. Tenders awarded to Pharmaceuticals where no brand is listed

Chemical name	Presentation; Pack size and type	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply date
Ramipril ²	Cap/tab 1.25 mg; 30 capsule blister pack	\$2.30	Tryzan (Viatris)	5%	1 December 2022	1 May 2023
Ramipril ²	Cap/tab 2.5 mg; 30 capsule blister pack	\$2.20	Tryzan (Viatris)	5%	1 December 2022	1 May 2023
Ramipril ²	Cap/tab 5 mg; 30 capsule blister pack	\$2.25	Tryzan (Viatris)	5%	1 December 2022	1 May 2023
Ramipril ²	Cap/tab 10 mg; 30 capsule blister pack	\$2.35	Tryzan (Viatris)	5%	1 December 2022	1 May 2023
² Ramipril capsules will be funded without restrictions from 1 December 2022. Details on this decision is <u>here</u>						

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

3. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Nortriptyline hydrochloride	Tab 10 mg; 100 tablet blister pack	\$2.44	\$2.46	Norpress (Viatris)	1 December 2022	1 May 2023
Nortriptyline hydrochloride	Tab 25 mg; 180 tablet blister pack	\$5.98	\$6.29	Norpress (Viatris)	1 December 2022	1 May 2023

4. Tenders awarded to Pharmaceuticals where at least one other brand is listed.

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Capecitabine	Tab 150 mg; 60 tablet blister pack	\$10.00	\$9.80	Capecitabine Viatris (Viatris)	1 August 2023	1 January 2024	Capercit (Dr Reddy's)
Capecitabine	Tab 500 mg; 120 tablet blister pack	\$49.00	\$46.50	Capecitabine Viatris (Viatris)	1 August 2023	1 January 2024	Capercit (Dr Reddy's)
Codeine phosphate	Tab 15 mg; 100 tablet blister pack	\$6.25	\$5.92	Noumed (Noumed)	1 December 2022	1 May 2023	PSM (API Consumer Brands)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

5. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Nortriptyline hydrochloride	Tab 10 mg; 100 tablet blister pack	\$2.44	\$2.46	Norpress (Viatris)	5%	1 December 2022	1 May 2023
Nortriptyline hydrochloride	Tab 25 mg; 180 tablet blister pack	\$5.98	\$6.29	Norpress (Viatris)	5%	1 December 2022	1 May 2023

6. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Capecitabine	Tab 150 mg; 60 tablet blister pack	\$10.00	\$9.80	Capecitabine Viatris (Viatris)	5%	1 August 2023	1 January 2024	Capercit (Dr Reddy's)
Capecitabine	Tab 500 mg; 120 tablet blister pack	\$49.00	\$46.50	Capecitabine Viatris (Viatris)	5%	1 August 2023	1 January 2024	Capercit (Dr Reddy's)
Codeine phosphate	Tab 15 mg; 100 tablet blister pack	\$6.25	\$5.92	Noumed (Noumed)	5%	1 December 2022	1 May 2023	PSM (API Consumer Brands)



Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the:

- 2019/20 Invitation to Tender, dated 1 November 2019; and the
- 2021/22 Invitation to Tender, dated 1 November 2021.

2019/20 Invitation to Tender

Chemical name	Line item
Docetaxel	Inj 20 mg
Docetaxel	Inj 80 mg
Exemestane	Tab 25 mg

2021/22 Invitation to Tender

Chemical name	Line item
Cetirizine hydrochloride	Tab 10 mg
Methylcellulose with glycerin and sodium saccharin	Suspension
Methylcellulose with glycerin and sucrose	Suspension
Permethrin	Crm 5%
Thiotepa	lnj 15 mg
Thiotepa	Inj 100 mg

Tender decisions on all products included in the 2019/20 Invitation to Tender have now all been announced. For products included in the 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.